Investor Frenzy Pushes Subscription Over 2x Despite Valuation Concerns Retail Investors Fuel Early Buzz as Groww IPO Sees 57% Subscription on Day 1 Democrats Push Back on GOP Claims That Biden ...

Q3 2025 Management View CEO A. Kazimi announced a new strategic agreement: "We've entered into arrangements with RedHill ...

The FDA has announced new rules for the approval of biosimilar drug products that could reduce 5- to 8-year timelines by half.

Alvotech, for its part, has run into repeated issues with the FDA at its Icelandic drug plant. Since the company’s biosimilar accord with Teva began, problems at the Reykjavik facility have led to two ...

Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...

David will provide an overview of our key business updates, Colleen will provide details on the commercial launch of Atrozy, ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

RevBio® announced today that TETRANITE, the company's first of its kind regenerative "bone glue" has been approved for a 20-patient pilot study to measure the biomaterial's safety and efficacy to ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

PE: How long will it take for the market to be impacted by FDA's ANDA Prioritization Pilot? Botha: It’s a relative window. It ...